Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | GHSR | Q92847 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857070 | 0.86 | POLB (0.74) | POLBRAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL10920778 | 0.84 | POLB (1.00) | POLBRAB9AALDH1A1CYP1A2GAA | |
| SCHEMBL9952997 | 0.82 | ALDH1A1 (0.55) | POLBRAB9AALDH1A1CYP1A2GAA | |
| SCHEMBL9954184 | 0.81 | POLB (0.47) | POLBRAB9AALDH1A1CYP1A2GAA | |
| SCHEMBL6799696 | 0.79 | RAB9A (0.63) | POLBRAB9ACYP1A2GAACYP2C9 | |
| SCHEMBL10288776 | 0.79 | POLB (0.46) | POLBRAB9AALDH1A1GAAKMT2A | |
| SCHEMBL6856171 | 0.78 | POLB (0.45) | POLBRAB9AALDH1A1GAAKMT2A | |
| SCHEMBL8515506 | 0.78 | RAB9A (0.62) | POLBRAB9AALDH1A1GAAKMT2A | |
| SCHEMBL10289053 | 0.78 | KDM4E (0.50) | POLBRAB9AALDH1A1CYP1A2GAA | |
| SCHEMBL9954352 | 0.77 | SMN1; SMN2 (0.66) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828315-B1 | Anti- inflammatories, anti-allergics, bronchodilatators, anti-asthmatics, or TNF alpha inhibitors | WARNER-LAMBERT LLC | 2004-12-07 | — | — | US | disclosed |
| US-6747035-B2 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | WARNER-LAMBERT LLC | 2004-06-08 | — | — | US | disclosed |
| EP-1419159-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO 4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | GUADILLIERE BERNARD (FR) | 2003-04-10 | — | — | US | disclosed |
| EP-1177195-B1 | 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV | WARNER LAMBERT CO (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2003016314-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO[4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1285922-A1 | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1177195-A1 | 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV | WARNER-LAMBERT COMPANY (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000066584-A1 | 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV | WARNER-LAMBERT COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | PDE3A, PDE4A, PDE5A | POLB 739/4885RAB9A 2106/4885ALDH1A1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.